Vir Biotechnology (NASDAQ:VIR) CFO Jason O’byrne Sells 6,799 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Jason O’byrne sold 6,799 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.56, for a total transaction of $37,802.44. Following the completion of the transaction, the chief financial officer directly owned 110,701 shares in the company, valued at $615,497.56. This trade represents a 5.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Vir Biotechnology Stock Up 0.2%

Shares of VIR stock opened at $5.50 on Wednesday. The company has a 50 day moving average of $5.59 and a 200-day moving average of $5.27. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $14.45. The firm has a market cap of $765.19 million, a P/E ratio of -1.52 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.56) earnings per share. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on VIR shares. Evercore ISI started coverage on Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vir Biotechnology in a research note on Wednesday, November 5th. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $12.00 to $14.00 in a report on Wednesday, August 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research report on Monday, September 15th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.30.

Institutional Trading of Vir Biotechnology

Several large investors have recently added to or reduced their stakes in VIR. Connective Capital Management LLC purchased a new position in shares of Vir Biotechnology during the third quarter worth $431,000. Sender Co & Partners Inc. purchased a new stake in shares of Vir Biotechnology during the third quarter worth $247,000. Dark Forest Capital Management LP purchased a new stake in shares of Vir Biotechnology during the third quarter worth approximately $817,000. XTX Topco Ltd acquired a new stake in Vir Biotechnology in the third quarter valued at approximately $799,000. Finally, Prelude Capital Management LLC purchased a new stake in shares of Vir Biotechnology during the 3rd quarter worth $108,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).